Haisco Pharmaceutical Group Co. Ltd. has disclosed new muscarinic M4 receptor agonists described as potentially useful for the treatment of substance abuse and dependence, Alzheimer’s disease, pain, schizophrenia and sleep disorders.

A patent from Hansoh Bio LLC, Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. describes new multi-membered macrocyclic compounds acting as GTPase KRAS G12C, G12V and/or G13D mutant inhibitors.

Alterity Therapeutics Ltd. has divulged salts of ATH-434, the company's oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration.

Shenzhen Hanlin Biomedical Technology Co. Ltd. has identified new urolithin A derivatives. They are reported to be useful for the treatment of neurological disorder, aging, muscle disorder and metabolic diseases.

Work at Alicorn Pharmaceutical Co. Ltd. has led to the synthesis of new sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers. They are reported to be useful for the treatment of pain, respiratory and neurological disorders.

Connecta Therapeutics SL has discovered 3-phenoxy-3-phenylpropanamine derivatives described as potentially useful for the treatment of fragile X and Rett syndrome.

Alchemedicine Inc. has disclosed complement factor D (CFD) inhibitors described as potentially useful for the treatment of age-related macular degeneration, arthritis, Alzheimer’s disease, multiple sclerosis, ulcerative colitis, diabetic retinopathy, glaucoma and autoimmune diseases.

A group at the University of Antwerp has patented ferroptosis inhibitors. They are reported to be useful for the treatment of acute renal failure, sepsis, ischemia-reperfusion injury and more.

Boehringer Ingelheim Pharma GmbH & Co. KG has synthesized peptide-lipid drug conjugates comprising a neuromedin U NMU2 receptor agonist peptide. They are reported to be useful for the treatment of obesity.

Astrazeneca AB has identified new quinazoline derivatives acting as gastric inhibitory polypeptide receptor (GIPR) antagonists. As such, they are described as potentially useful for the treatment of colitis, diabetes, inflammatory bowel disease, osteoporosis, psoriasis, schizophrenia, thrombosis and Alzheimer’s disease among others.